Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 1
1976 3
1977 1
1979 2
1980 1
1984 3
1985 2
1986 3
1987 1
1988 1
1989 4
1990 2
1991 1
1992 1
1993 2
1994 1
1995 4
1996 3
1998 2
1999 3
2001 2
2002 1
2003 2
2004 1
2005 3
2006 2
2007 1
2009 2
2010 4
2011 2
2012 4
2013 4
2014 3
2015 1
2016 4
2017 4
2018 4
2019 2
2020 4
2021 4
2022 7
2023 9
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. Luke JJ, et al. Among authors: asch as. Nat Med. 2023 Nov;29(11):2814-2824. doi: 10.1038/s41591-023-02593-0. Epub 2023 Oct 19. Nat Med. 2023. PMID: 37857711 Free PMC article. Clinical Trial.
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Sallman DA, et al. Among authors: asch as. J Clin Oncol. 2023 May 20;41(15):2815-2826. doi: 10.1200/JCO.22.01794. Epub 2023 Mar 8. J Clin Oncol. 2023. PMID: 36888930 Free PMC article. Clinical Trial.
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ. Pratz KW, et al. Among authors: asch a. J Clin Oncol. 2023 Sep 10;41(26):4236-4246. doi: 10.1200/JCO.22.02721. Epub 2023 Jun 28. J Clin Oncol. 2023. PMID: 37379495 Clinical Trial.
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma.
Maakaron JE, Asch A, Popplewell L, Collins GP, Flinn IW, Ghosh N, Keane C, Ku M, Mehta A, Roschewski M, Hacohen-Kleiman G, Huo Y, Zhang Y, Renard C, Smith SM, Advani R. Maakaron JE, et al. Among authors: asch a. Blood Adv. 2024 Nov 26;8(22):5864-5874. doi: 10.1182/bloodadvances.2024013338. Blood Adv. 2024. PMID: 39293083 Free PMC article. Clinical Trial.
Immunoprevention of Pancreatic Cancer.
Rao CV, Mohammed A, Asch AS, Janakiram NB. Rao CV, et al. Among authors: asch as. Curr Med Chem. 2018;25(22):2576-2584. doi: 10.2174/0929867324666170223153509. Curr Med Chem. 2018. PMID: 28240168 Review.
A duty to discriminate?
Wasserman D, Asch A. Wasserman D, et al. Among authors: asch a. Am J Bioeth. 2012;12(4):22-4. doi: 10.1080/15265161.2012.656814. Am J Bioeth. 2012. PMID: 22452470 No abstract available.
114 results